Shares in ResMed (NYSE:RMD) fell nearly 20% after the respiratory-focused medical device maker missed sales expectations on Wall Street with its second quarter earnings results. The San Diego-based company posted profits of $124.6 million, or 86¢ per share, on sales of $651.1 million for the three months ended December 31, for massive bottom-line growth of approximately […]
ResMed Inc.
ResMed closes $225m Propeller Health purchase
ResMed (NYSE:RMD) said yesterday that it completed its $225 million acquisition of Propeller Health and its digital medicine platform. Lead by CEO David Van Sickle, Propeller will continue to operate as a standalone business within ResMed’s respiratory care portfolio, the companies reported. Get the full story at our sister site, Drug Delivery Business News.
ResMed’s Brightree picks up Apacheta
ResMed (NYSE:RMD) subsidiary Brightree said this week that it paid an undisclosed amount to bolster its software-as-a-service holdings with Apacheta. Media, Pa.-based Apacheta makes mobile apps that allow companies to automate and streamline business processes in sales, marketing, logistics and field services. “Apacheta solves many of the business challenges [home medical equipment companies] face in managing deliveries, particularly […]
ResMed puts $225m on the table for Propeller Health
ResMed (NYSE:RMD) said today that it inked a deal to acquire Propeller Health and its digital medicine platform for $225 million in cash. Propeller Health, which sells small sensors that attach to inhalers and track medication use, will operate as a standalone business under ResMed’s respiratory care portfolio. Get the full story at our sister site, Drug Delivery […]
ResMed closes $750m MatrixCare buy
ResMed (NYSE:RMD) said today that it closed the $750 million acquisition of MatrixCare and its post-acute-care software. The San Diego-based respiratory care giant said it funded the buyout, which represents a 25x EBITDA multiple, using its credit facility. Bloomington, Minn.-based MatrixCare put up sales of $122 million last year, ResMed said. “We’re all excited to have quickly closed this important […]
ResMed to pay $750m for MatrixCare
ResMed (NYSE:RMD) said today that it agreed to pay $750 million to acquire MatrixCare and its post-acute-care software. The San Diego-based respiratory care giant said it plans to fund the buyout, which represents a 25x EBITDA multiple, using its credit facility. Bloomington, Minn.-based MatrixCare put up sales of $122 million last year, ResMed said. “The acquisition of MatrixCare is […]
ResMed’s fiscal Q1 tops forecast
ResMed (NYSE:RMD) yesterday reported fiscal first-quarter results that beat the consensus forecast. The San Diego-based respiratory device maker posted profits of $105.7 million, or 73¢ per share, on sales of $588.3 million for the three months ended Sept. 30, for bottom-line growth of 22.8% on sales growth of 12.3% compared with fiscal Q1 2018. Adjusted to […]
ResMed touts German win in continued Fisher & Paykel patent spat
ResMed (NYSE:RMD) yesterday touted a win in a German patent spat over masks used with continuous positive airway pressure machines with competitor Fisher & Paykel Healthcare (NZE:FPH). San Diego-based ResMed said that a trial court ruling from Germany’s Munich District Court found that Fisher & Paykel’s Simplus full face and Eson 2 nasal mask head gear infringes […]
ResMed files suits in continued patent spat with Fisher & Paykel
ResMed (NYSE:RMD) said late last week it filed a patent infringement petition with the US International Trade Commissions against competitor Fisher & Paykel Healthcare (NZE:FPH) in a continued spat between the companies. San Diego-based ResMed said they also filed a new lawsuit against Fisher & Paykel seeking monetary damages related to patent infringement from the company, as […]
ResMed ventilator now has autoEPAP
ResMed (NYSE:RMD) has added autoEPAP to its Astral life support ventilator in the United States. AutoEPAP (automatic expiratory positive airway pressure) automatically adjusts a patient’s expiratory pressure in response to flow limitations or obstruction of the upper airway. It’s an option when in Astral’s iVAPS (intelligent volume-assured pressure support) mode that automatically adapts to a patient’s […]
ResMed shares down as FY2018 earnings show shrinking profits
Shares in ResMed (NYSE:RMD) have fallen today after the medical device maker posted fourth quarter and full fiscal year 2018 earnings that topped expectations on the Street, but showed full year profits decline when compared to 2017. The San Diego-based company posted profits of $109.8 million, or 76¢ per share, on sales of $623.6 million for […]